(See the editorial commentary by Brunham on pages 1796-7.)
Genital Chlamydia trachomatis infection (chlamydia) is a major public health burden. Chlamydia is the most common bacterial sexually transmitted infection (STI) in the United States and worldwide [1] [2] [3] . Over 1.3 million chlamydia cases were reported to the US Centers for Disease Control and Prevention (CDC) in 2010, with a calculated rate of 426 cases per 100 000 population [1] ; this represents the highest rate of any reportable infection in the United States recorded by CDC surveillance [4] . However, reported cases underestimate the true burden of infection. It has been previously estimated that the annual number of new chlamydial infections worldwide is approximately 92 million [3] and for the United States is approximately 3 million [2] . Chlamydia is most common among adolescents and young adults [1] . Untreated chlamydia is associated with serious complications in women, including pelvic inflammatory disease, ectopic pregnancy, and infertility; chlamydia is a leading preventable cause of infertility worldwide. Despite chlamydia prevention and control efforts (including routine annual chlamydia screening in young sexually active women, prompt chlamydia treatment, partner treatment, and retesting for repeat infection), chlamydia prevalence in the United States has not significantly declined [1, 5] .
The natural history of chlamydia in humans is variable. Untreated chlamydia may persist without symptoms for long periods, may progress to cause complications, or may resolve spontaneously without treatment ("self-cure"). Reinfection is common after therapy, occurring in about 10%-20% of patients within 12 months [6] [7] [8] ; this suggests chlamydia does not elicit protective immunity in some patients. On the other hand, there is also evidence suggesting that host immune responses can control chlamydia naturally under certain circumstances. We and others have observed that about 20% of chlamydia-infected patients without signs of infection, who are diagnosed through screening, experience spontaneous resolution of their infection in the interval between their initial chlamydia screening test and returning for treatment for the positive test [9] [10] [11] . Neither the host factors contributing to spontaneous resolution of chlamydia in humans nor the clinical implications of spontaneous resolution have been fully elucidated. However, murine models of chlamydia demonstrate that when primary chlamydial infection resolves in the absence of therapy, it results in immunity against subsequent reinfection [12] . We hypothesized that spontaneous resolution of chlamydia in humans would be associated with a decreased risk for reinfection, and undertook a prospective study in women returning for treatment of a positive chlamydia screening test to evaluate the influence of spontaneous resolution on the risk for chlamydia reinfection. If the hypothesis is supported by the study findings, then this would suggest chlamydia treatment before natural resolution of infection could attenuate development of protective immunity in some patients, and stresses the need for an effective chlamydia vaccine to improve chlamydia prevention efforts.
MATERIALS AND METHODS

Study Design and Study Population
We prospectively collected data on the natural history of untreated chlamydia in the interval between testing and treatment and the epidemiology of chlamydia reinfection in women enrolled between January 2008 and June 2011. The study was approved by the University of Alabama at Birmingham (UAB) and Jefferson County Department of Health ( JCDH) institutional review boards. Written informed consent was obtained from all patients who participated in the study. The study population was comprised of women ≥16 years of age presenting to the JCDH Sexually Transmitted Disease (STD) Clinic in Birmingham, Alabama, for treatment of a positive chlamydia screening test. A 60-day maximum time interval between screening and returning for treatment was chosen to minimize confounding factors such as unreported interval treatment or exposure to a new chlamydial infection. The chlamydia test used during the study period was the Gen-Probe Aptima Combo 2 (GP AC2; Gen-Probe, San Diego, CA) nucleic acid amplification test, performed according to the manufacturer's protocol. Although many women tested for chlamydia in the clinic are empirically treated at the time of initial evaluation for a chlamydia-associated syndrome or as a recent sexual contact to a potentially chlamydia-infected partner, only women who had not received antibiotics effective for C. trachomatis at the time of screening or in the interval between screening and returning to the clinic for treatment were eligible for study inclusion. We excluded women who were pregnant or had a prior hysterectomy.
Study Participant Recruitment and Follow-Up
Women were recruited for the study at the time they presented to the clinic for treatment of a positive chlamydia screening test (all screening tests had been performed on cervical swab specimens). At enrollment, participants were interviewed by either a research study coordinator or an investigator and had their clinic record reviewed. The following data were then recorded on a data collection form: demographic characteristics, sexual history (including STI history and risk factors), hormonal contraception use, condom use, antibiotic use, and reported partner treatment. Urine was collected for a pregnancy test, and a pelvic examination was performed to obtain a vaginal swab specimen for a wet mount and a cervical swab specimen for chlamydia and gonorrhea testing by GP AC2. All participants received directly observed therapy with azithromycin 1 g (consisting of 2 azithromycin 500 mg tablets) and were encouraged to refer all sexual partners for treatment if not already treated. A follow-up visit was scheduled for approximately 6 months. We included data for determining reinfection status from any follow-up visit between 1 to 12 months after treatment if this was the time the patient returned to the study staff at the clinic. Follow-up earlier than 1 month was not deemed evaluable for reinfection because of concern that a false positive GP AC2 result could occur from insufficient time to permit clearance of residual C. trachomatis nucleic acids from nonviable organisms from the genital tract [13] [14] [15] . At the follow-up visit, participants were interviewed and had their clinic record reviewed to obtain the same information collected at enrollment, other than demographic characteristics, and also were asked about partner treatment, new sexual partners since treatment, and occurrence of any interim visits in which antibiotics may have been taken or STI testing was performed and, if tested, the results of the tests (an unscheduled visit occurred in about 20% of participants). Cervical swabs were again collected for chlamydia and gonorrhea testing by GP AC2.
Statistical Analysis
Patients were classified as either having spontaneous resolution of chlamydia or persisting chlamydial infection at the time of enrollment (time of treatment) based on negative or positive chlamydia test results, respectively, from the GP AC2 performed at that visit. Univariate associations between spontaneous resolution status and other participant characteristics with reinfection between 1-12 months after treatment were investigated using Pearson's χ 2 or Fisher's exact test for categorical characteristics and the Wilcoxon rank sum test for continuous variables (ie, length of follow-up). Variables that were significant at the α = 0.10 level were candidates for inclusion in a multivariable logistic regression model, and variables maintaining significance at the α = 0.10 level were retained in the model. Model fit was assessed using deviance and Pearson goodness of fit tests. Given the association among predictor variables, likelihood ratio P values were computed. To characterize bias associated with being lost to follow-up, univariate analyses of participant baseline characteristics according to follow-up status were performed. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
Of 245 women enrolled, 200 (81.6%) returned for a follow-up visit. Study participant characteristics at enrollment for those who returned for a follow-up visit can be found in Table 1 . The study population was predominantly African American (93.5%) with a median (range) age of 22 (16-54) years. The majority (56.0%) had a history of prior chlamydia (by patient report and/or review of prior laboratory testing). Bacterial vaginosis was frequently diagnosed at enrollment (31.0%), but other genital infections occurred more rarely. Spontaneous resolution of chlamydia was demonstrated in 44 participants (22.0%) at enrollment (the time when patients returned for treatment of a positive chlamydia screening test), with a median interval between screening and enrollment of 15 days (range 6-47 days).
To characterize the bias due to participants being lost to follow-up, participant characteristics were compared according to follow-up status. There were no significant differences in terms of spontaneous resolution of chlamydia at enrollment, which occurred in 22% of participants in those with and without follow-up visits. There were also no significant differences by age, race, or history of prior chlamydia. There was a lower median number of sexual partners in the prior 6 months for those lost to follow-up as compared to those who were not, although this was not statistically significant (median Table 2 . Spontaneous resolution status at enrollment and age were each significantly associated with reinfection status in univariate analyses (Table 2 and Figure 1 ). Compared to participants with spontaneous resolution of chlamydia demonstrated at enrollment, a higher proportion of those with persisting infection had reinfection at the follow-up study visit ( Spontaneous chlamydia resolution status at enrollment, age, and reported partner treatment met the multivariate model inclusion criteria, but reported partner treatment did not meet the retention criteria after adjusting for resolution status and age (P = .123). After adjusting for age, the odds of chlamydia reinfection was 4 times higher for participants with persisting infection demonstrated at enrollment compared with those with spontaneous resolution (OR 4.0, 95% CI, 1.1-25.6; P = .034) (Figure 1) . Also, the odds of reinfection was 3.0 times higher for participants aged <25 years as compared to those who were older (OR 3.0, 95% CI, 1.2-9.2; P = .022). The goodness-of-fit tests were not rejected, indicating adequate model fit. 
DISCUSSION
An understanding of the natural history of chlamydia in humans and the potential for development of protective immunity is important both for chlamydia screening recommendations and for efforts to develop chlamydial vaccines. We and others have observed that about 20% of chlamydia-infected patients experience spontaneous resolution of infection in the interval between chlamydia screening and returning for treatment of a positive test [9] [10] [11] , providing evidence that host immune responses can eradicate chlamydia in the absence of antimicrobial therapy. Murine models of genital chlamydia have demonstrated that resolution of untreated infection leads to development of protection against reinfection [12] , but do humans develop protection against reinfection after spontaneous resolution? Our data suggest that the answer is yes. Our study is the first to demonstrate an association of natural resolution of genital chlamydial infection in humans with a decreased risk for reinfection. Other than the prior human ocular challenge experiments and vaccine trials with trachoma (ocular infection due to unique C. trachomatis serovars) demonstrating resistance to repeat trachoma infection [16, 17] , our study provides some of the most direct evidence to date supporting protective immunity to C. trachomatis reinfection in humans. Indirect evidence from studies using either documented prior chlamydia or older age in populations at risk for chlamydia as surrogates for protective immunity to chlamydia also support the notion that humans develop protective immunity. For example, a study of STD clinic attendees demonstrated that prior documented chlamydia was associated with a reduced risk of reinfection, although resistance to reinfection appeared to be of limited duration [18] . Another example includes a study of female sex workers that found that longer duration of prostitution was associated with reduced risk for chlamydia [19] . In our study, we found that older age (≥25 years) was associated with a lower risk for reinfection, but prior chlamydia was not associated with reinfection. Data from US CDC chlamydial surveillance [1] , from a US managed care population database [20] , and from a nationally representative survey [5] have all demonstrated low chlamydia prevalence rates in women ≥25 years of age, and such data are used in determining the age cutoff for chlamydia screening recommendations in women [13, 21] . While lower chlamydia prevalence in older age groups may, in part, reflect lower behavioral risk, it may also reflect protective immunity that developed from repeated chlamydia exposures in a subset of the older population. Although we collect self-reported data and review patients' medical records to assess for a history of prior chlamydia, we still cannot exclude the possibility that subjects without a reported history of chlamydia still might have had prior chlamydia. It is likely that prior chlamydia is underrecognized in populations with a high chlamydia prevalence (eg, an STD clinic population such as in our study), and this could have led to misclassification of prior chlamydia in our study.
Our study reaffirms that up to 20% of women who test chlamydia-positive at the time of treatment will have subsequent reinfection within a year of treatment for infection. This relatively high rate of chlamydia reinfection after therapy may suggest that some infected individuals do not develop protective immunity. Duration of infection and timing of treatment may modify resistance to future infection. In a murine chlamydia model, antibiotic treatment given before immune responses were fully developed impaired development of protective immunity [22] . Our study did not have sufficient information on previous sexual behaviors and chlamydia testing that would allow us to determine the duration of infection prior to therapy (ie, time between infection acquisition and treatment). Recent population-based studies from Canada have reported high chlamydia reinfection rates [23, 24] ; it has been suggested that this may be, in part, due to early treatment of chlamydia through a chlamydia control program leading to attenuated development of immunity and, as a result, increased susceptibility to reinfection ("the arrested immunity hypothesis") [25] . Although chlamydia control efforts with increases in chlamydia screening and treatment appear beneficial in decreasing the incidence of chlamydia complications [20, [26] [27] [28] [29] , this could be leading to more chlamydia reinfections due to attenuated immunity, and stresses the need for a chlamydia vaccine Figure 1 . Forest plot of odds ratios and 95% CI for chlamydia reinfection at follow-up based on chlamydia resolution status at enrollment (time of treatment) and age. Estimates to the right of the vertical line indicate reinfection is more likely, and those to the left indicate reinfection is less likely. When the 95% confidence interval does not cross the vertical line, then the odds ratio is significantly different from 1. Unadjusted results are from separate univariate analyses for chlamydia resolution status at enrollment (the time of treatment) and age. Adjusted results are estimates from a multivariable model, including chlamydia resolution status at enrollment and age as independent variables. Abbreviation: CI, confidence interval.
to further assist in chlamydia prevention efforts. Until a safe, effective chlamydia vaccine is available, it will be important to continue to provide chlamydia treatment to minimize the risk for complications, many of which are subclinical or silent.
Our study is not without other limitations. The study population was women, mostly African American, evaluated in an STD clinic setting. It is unknown whether our study findings will be applicable to populations with different demographics and/or clinical settings. The race distribution of our study population is representative of the population of women routinely seen at the JCDH STD Clinic. Men evaluated at STD clinics are difficult to enroll in such a natural history study design because they are often empirically treated for urethritis before chlamydia test results are known, prohibiting the opportunity to evaluate for spontaneous resolution before returning for treatment of a positive test. One may question whether the initial chlamydia screening test was a false-positive and that subjects classified as spontaneously resolved may have not been infected. This is highly unlikely for most subjects considering the high specificity (99%) of GP AC2 on cervical specimens and the high positive predictive value (PPV) in our clinic population (PPV 94% using an approximate chlamydia prevalence of 11% for our population) [30] . The CDC does not recommend a confirmatory nucleic acid amplification test in populations with ≥90% PPV [31] . While we believe most repeat positive tests at follow-up were due to reinfection (from a current or new partner), we cannot exclude the possibility that a small number of these could have been persisting infection due to azithromycin treatment failure. A recent study reported a high rate of azithromycin treatment failure in men with symptomatic chlamydia urethritis [32] , although other recent studies suggest most chlamydia-infected women treated with azithromycin are cured [33, 34] . We also cannot exclude the possibility that C. trachomatis genotype differences could influence risk for chlamydia persistence and/or reinfection, and future chlamydia natural history studies aimed at understanding these outcomes should consider incorporating C. trachomatis genotyping. The duration of follow-up for up to 12 months in our study only provides the opportunity to evaluate short-term immunity, and it is possible as has been suggested [18, 19] that human immunity to chlamydia may only be short-lived. Longer prospective follow-up in an STD clinic population can be challenging, as evidenced by the already 18% lost to follow-up in our study with follow-up of up to 12 months. The lack of significant differences in spontaneous resolution rate and most other patient characteristics in those who were versus were not lost to followup provides some reassurance that study outcomes were not greatly biased by participants lost to follow-up. Finally, understanding how the course of untreated chlamydia may be modified by host immune responses requires further in-depth investigation. While murine studies indicate CD4 + T-helper type 1 immune responses are essential for chlamydia resolution and protection against reinfection [12] , effector immune mechanisms may differ in humans. In summary, we present the first evidence in humans that spontaneous resolution of genital chlamydial infection is associated with decreased risk for reinfection. A challenge ahead of us will be to understand the immune mechanisms that contribute to resolution of infection and development of protective immunity. It will also be important to identify genetic determinants that modulate the immune responses. Such knowledge could provide correlates of protective immunity necessary for the development of an effective chlamydia vaccine.
Notes
